TEMPUS
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful.
TEMPUS
Industry:
Artificial Intelligence (AI) Biotechnology Health Care Machine Learning Medical Precision Medicine
Founded:
2015-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.tempus.com
Total Employee:
501+
Status:
Active
Contact:
(800) 976-5448
Total Funding:
1.35 B USD
Technology used in webpage:
IPv6 Cloudflare Hosting Google Google Cloud U.S. Server Location CrUX Top 50m Apple Mobile Web App Capable Cloudflare CDN BootstrapCDN Cloudflare
Similar Organizations
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
doc.ai
doc.ai is a digital health company designed for a new generation of medical research.
Genomind
Genomind is a personalized medicine company specializing in neuropsychiatry.
Genuity Science
Contract genomics organization offering robust data sourcing, data analytics and insights, and next gen sequencing for drug discovery.
Perceiv AI
AI-driven precision medicine, forecasting disease progression
Prenosis
Transforming clinical diagnosis with predictive intelligence.
Scailyte
True precision medicine through single-cell science
Sweetch
Sweetch is the first behavioral science company to leverage AI & EI (emotional intelligence) through its digital therapeutics solutions.
Current Advisors List
Board_member
Board_member
Board_member
2015-01-01
Current Employees Featured
Ryan Fukushima Chief Operating Officer @ Tempus
Chief Operating Officer
2015-01-01
Eric Lefkofsky Founder and CEO @ Tempus
Founder and CEO
2015-01-01
Shane Colley CTO @ Tempus
CTO
2017-01-01
Erik Phelps Executive Vice President, Chief Administrative and Legal Officer @ Tempus
Executive Vice President, Chief Administrative and Legal Officer
2020-06-01
Lauren Silvis Senior Vice President, External Affairs @ Tempus
Senior Vice President, External Affairs
2019-08-01
Riccardo Miotto Director of Machine Learning @ Tempus
Director of Machine Learning
2021-03-01
David Landeck Senior Director of Product @ Tempus
Senior Director of Product
Nadav Weinberg Head of Enterprise Infectious Disease Partnerships @ Tempus
Head of Enterprise Infectious Disease Partnerships
2020-05-01
Jonathan Ozeran Vice President, Generative AI and Head of Tempus One @ Tempus
Vice President, Generative AI and Head of Tempus One
2023-07-01
Yannick Pouliot Principal Genomic Data Scientist @ Tempus
Principal Genomic Data Scientist
2021-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-27 | Dawson Forte Cashmere | Dawson Forte Cashmere acquired by Tempus | N/A |
| 2023-03-09 | Mpirik | Mpirik acquired by Tempus | N/A |
| 2023-02-10 | Arterys | Arterys acquired by Tempus | N/A |
| 2022-10-05 | Arterys | Arterys acquired by Tempus | N/A |
| 2022-02-08 | Highline Sciences | Highline Sciences acquired by Tempus | N/A |
| 2019-12-11 | AKESOgen | AKESOgen acquired by Tempus | N/A |
Investors List
Ares Management
Ares Management investment in Debt Financing - Tempus
Google investment in Debt Financing - Tempus
T. Rowe Price
T. Rowe Price investment in Series G - Tempus
Novo Holdings
Novo Holdings investment in Debt Financing - Tempus
Baillie Gifford
Baillie Gifford investment in Series G - Tempus
Franklin Templeton
Franklin Templeton investment in Debt Financing - Tempus
Google investment in Series G - Tempus
Baillie Gifford
Baillie Gifford investment in Debt Financing - Tempus
Franklin Templeton
Franklin Templeton investment in Series G - Tempus
Eric Lefkofsky
Eric Lefkofsky investment in Series G - Tempus
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-06-20 | Akrivia Health | Tempus investment in Series A - Akrivia Health | 4.3 M GBP |
| 2018-04-09 | 8Trip | Tempus investment in Series C - 8Trip | 600 M CNY |
| 2017-09-27 | Exicure | Tempus investment in Venture Round - Exicure | 20 M USD |
| 2015-10-21 | Exicure | Tempus investment in Venture Round - Exicure | 14.8 M USD |
Newest Events participated
Participated in GOTO Chicago 2017
on 2017-05-01 as sponsor
Official Site Inspections
http://www.tempus.com Semrush global rank: 258.39 K Semrush visits lastest month: 158.51 K
- Host name: 146.190.199.140
- IP address: 146.190.199.140
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tempus"
About Us - Tempus
Tempus is a technology company that has built the world's largest library of clinical and molecular data and an operating system to make that information accessible and useful for patients, …See details»
Tempus - Crunchbase Company Profile & Funding
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is …See details»
Tempus AI - Wikipedia
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence to create precision medicine solutions, including diagnostics, for oncology, cardiology, and depression. The company went public on June 14, 2024 under the ticker symbol "TEM." See details»
Our History - Tempus
Our History. Tempus was founded in August of 2015 by Eric Lefkofsky, after his wife was diagnosed with Breast Cancer. Shortly after he founded the company in an effort to bring the power of technology and artificial intelligence to cancer …See details»
Investor Relations | Tempus AI
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare to create Intelligent Diagnostics. …See details»
Tempus | SoftBank Group Corp. - ソフトバンクグルー …
Tempus brings the power of data and artificial intelligence to healthcare. It has a clear mission — to help make sure patients are on the right drug at the right time, so they can live longer and healthier lives. Launched in the United States in …See details»
Tempus Company Profile | Management and Employees List
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real …See details»
Investor FAQs - Tempus AI
Does Tempus pay dividends? To date, we have not paid a cash dividend on our common stock since going public. Who is your transfer agent? Our transfer agent is the American Stock …See details»
Tempus | The Healthcare Technology Report.
Shane Colley is the Chief Technology Officer at Tempus. Prior to joining Tempus, Colley was Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he built and led a global organization of over 200 …See details»
Tempus - Crunchbase Company Profile & Funding
Tempus is a decentralized community of builders, creators, and connectors led by Tempus Labs to build some of the most innovative DeFi products. Tempus is building the most important blocks of DeFi and Web3 in a way that’s scalable …See details»
Tempus Technologies - Crunchbase Company Profile & Funding
Tempus Technologies is an expert on secure payments that delivers secure and innovative payment-processing solutions for businesses of every size. Tempus Technologies' mission is …See details»
Tempus - Overview, News & Similar companies | ZoomInfo.com
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2 CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a …See details»
Tempus AI founder Eric Lefkofsky touts strong 2024 financials
1 day ago AI medicine company Tempus released a peak at its 2024 financials during yesterday's J.P. Morgan Healthcare Conference, saying its revenue of about $693 million …See details»
Tempus - Funding, Financials, Valuation & Investors - Crunchbase
Tempus has a post-money valuation in the range of $1B to $10B as of Oct 20, 2022, according to PrivCo. Sign up for a free trial to view exact valuation and search companies with similar …See details»
Tempus is Now an In-Network Provider for Humana, Expanding …
Jan 24, 2024 Tempus, a leader in artificial intelligence and precision medicine, today announced that the company has signed agreements for in-network provider status with Humana Inc. …See details»
Tempus AI Reports Preliminary 2024 Revenue of $693 Million, …
2 days ago Tempus AI (TEM, Financials) announced preliminary, unaudited financial results for 2024, reporting annual revenue of $693 million, a 30% year-over-year increase, and fourth …See details»
Tempus | AI Webinar
Prior to Tempus, she held clinical development positions at Foundation Medicine and AbbVie. Dr. Nimeiri is a dedicated oncologist. She brings expertise in clinical trial design, drug …See details»
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 …
Dec 31, 2024 CHICAGO --(BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and …See details»
Tempus Webinar | Outcomes Research
Emilie Scherrer is the Senior Director and Head of Head of Strategy, HEOR at Tempus AI and is a member of the RWE Alliance. Emilie was previously the Global Director of Health Economics …See details»
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 …
2 days ago Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, …See details»